Version 1
: Received: 13 July 2023 / Approved: 13 July 2023 / Online: 14 July 2023 (09:18:55 CEST)
How to cite:
Torres, T. Complementary Use of a Next-Generation Emollient Plus and Pimecrolimus in Atopic Dermatitis: A Case Report. Preprints2023, 2023070971. https://doi.org/10.20944/preprints202307.0971.v1
Torres, T. Complementary Use of a Next-Generation Emollient Plus and Pimecrolimus in Atopic Dermatitis: A Case Report. Preprints 2023, 2023070971. https://doi.org/10.20944/preprints202307.0971.v1
Torres, T. Complementary Use of a Next-Generation Emollient Plus and Pimecrolimus in Atopic Dermatitis: A Case Report. Preprints2023, 2023070971. https://doi.org/10.20944/preprints202307.0971.v1
APA Style
Torres, T. (2023). Complementary Use of a Next-Generation Emollient Plus and Pimecrolimus in Atopic Dermatitis: A Case Report. Preprints. https://doi.org/10.20944/preprints202307.0971.v1
Chicago/Turabian Style
Torres, T. 2023 "Complementary Use of a Next-Generation Emollient Plus and Pimecrolimus in Atopic Dermatitis: A Case Report" Preprints. https://doi.org/10.20944/preprints202307.0971.v1
Abstract
Atopic dermatitis (AD) is a chronic skin disease marked by inflammation, erythema, dryness and pruritic lesions. Due to the intermittent nature of the disease, management strategies for AD focus on flare prevention following remission. A 24-year-old patient with mild-to-moderate AD lesions, previously non-responsive to topical corticosteroids (TCS), was treated with pimecrolimus for 12 days and emollient plus cream (EC) every day. After the initial 12-day treatment course, the patient was advised to use pimecrolimus if his symptoms reoccured. AD symptoms improved substantially between Weeks 0 and 12 with daily use of EC. However, by Week 12, his symptoms had relapsed, necessitating retreatment with pimecrolimus. Overall, the patient experienced flare-free periods between Weeks 3 and 12 and between Weeks 13 and 16. No tolerability issues were reported. This case report demonstrates the use of a complementary approach of daily administration of maintenance EC and intermittent application of pimecrolimus for flare management, which was effective for treating a patient with mild-to-moderate AD resistant to TCS.
Keywords
atopic dermatitis; emollient plus cream; topical corticosteroids; topical calcineurin inhibitors; case report
Subject
Medicine and Pharmacology, Dermatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
